Pharmidex
Pharmidex is a UK-based preclinical Contract Research Organisation providing GLP, AAALAC and MHRA-accredited bioanalysis, preclinical and clinical services — including toxicology, pharmacokinetics, histology and biomarker analysis — to pharmaceutical, biotechnology and academic clients globally.
- Company typePrivate
- Founded2002
- HeadquartersLondon, United Kingdom
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Pharmidex does
Pharmidex is a UK-based preclinical Contract Research Organisation (CRO) providing integrated drug discovery and development services to pharmaceutical and biotechnology companies. The company operates from a London headquarters for business development and corporate functions, with state-of-the-art preclinical facilities in Hertfordshire comprising an 800m²+ licensed in vivo vivarium and 300m²+ laboratory space. The firm holds a comprehensive regulatory stack — MHRA, AAALAC, GLP and GCP accreditations — that allows it to generate submission-grade preclinical and clinical data.
The core offering is organized around three integrated service pillars: Bioanalysis (biomarker analysis, discovery and regulatory bioanalysis, drug metabolism, flow cytometry on an Attune NxT acoustic cytometer, haematology on a Siemens ADVIA 2120, and physicochemical assessment using UHPLC-HRMS and LC-MS/MS); Preclinical Services (histology, inflammation models, in silico drug discovery, medical device testing, medicinal chemistry, pharmacokinetics, toxicology, and the vivarium facility itself); and Clinical Services (clinical chemistry on a Thermo Scientific Indiko Plus, haematology and regulatory bioanalysis). Therapeutic-area expertise spans CNS, oncology, stroke, respiratory, metabolic disorders (obesity, diabetes, NASH, ADPKD) and autoimmune disease. Recent commercial additions include Tailored Genetically Altered Breeding Solutions launched in May 2026.
Pharmidex operates a fee-for-service professional services model, billing clients per project or study under quote-based contracts negotiated through direct enterprise sales and senior-scientist-led business development. The customer base spans 400+ global clients across 24 countries, including Top 25 Pharma companies and multi-programme biotechnology firms requiring IND-enabling pharmacology, bioanalysis and safety support. The company markets via its website, conference participation (e.g., ATS 2026), email newsletter and LinkedIn. The firm is privately held with no disclosed external investors or ownership changes in the input data.
Pharmidex firmographics
Firmographics- Name
- Pharmidex
- Legal name
- Pharmidex
- Website
- https://pharmidex.com
- Company type
- Private
- Founded year
- 2002
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Pharmidex is a UK-based preclinical Contract Research Organisation providing GLP, AAALAC and MHRA-accredited bioanalysis, preclinical and clinical services — including toxicology, pharmacokinetics, histology and biomarker analysis — to pharmaceutical, biotechnology and academic clients globally.
- Ownership category
- akta.pro rank
Pharmidex industry classification
Industry- Product category
- Preclinical Contract Research Services
- NAICS
- Scientific Research and Development Services (5417)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Preclinical CROs (Discovery/Pharmacology/DMPK) (HLAGAAAB)
- akta.pro secondary industries
- DMPK / ADME & Bioanalysis (HLAGAFAC), Toxicology & Safety Assessment CROs (GLP) (HLAGAAAC), Central Laboratory & Clinical Trial Testing CROs (HLAGAAAE), Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL)
Keywords
Where Pharmidex is headquartered
LocationHeadquarters
- HQ city
- London
- HQ country
- United Kingdom
- HQ region
- Europe
Offices2 records
Markets served
Pharmidex business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Infrastructure, Technology or R&D, Operations, Marketing or Sales
Revenue model
- Preclinical Contract Research Services: Fee-for-service preclinical CRO services including bioanalysis, preclinical studies, and clinical sample analysis billed per project or study contract
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
Pharmidex product offering
Product offeringCore offering
Pharmidex is a UK-based preclinical Contract Research Organisation (CRO) that delivers fee-for-service drug discovery and development support across three integrated pillars: Bioanalysis (biomarker analysis, discovery and regulatory bioanalysis, drug metabolism, physicochemical assessment, flow cytometry, haematology), Preclinical Services (histology, inflammation, in silico drug discovery, medicinal chemistry, medical device testing, pharmacokinetics, toxicology, vivarium), and Clinical Services (clinical chemistry, haematology, regulatory bioanalysis). The company serves pharma, biotech, and academic clients with GLP-, GCP-, MHRA-, and AAALAC-accredited workflows across therapeutic areas including CNS, oncology, stroke, respiratory, metabolic, and autoimmune diseases.
Product overview
Pharmidex is a UK-based preclinical Contract Research Organisation (CRO) providing integrated drug discovery and development services. The company operates as a single-site, scientifically rigorous CRO focused on complex preclinical decision-making. The core offering consists of three integrated service pillars: Bioanalysis (including biomarker analysis, discovery bioanalysis, drug metabolism, flow cytometry, haematology, and regulatory bioanalysis), Preclinical Services (covering histology, inflammation, in silico drug discovery, medical device testing, medicinal chemistry, pharmacokinetics, toxicology, and vivarium facilities), and Clinical Services (including clinical chemistry, haematology, and regulatory bioanalysis). The company also provides specialised therapeutic area expertise in CNS, oncology, stroke, respiratory, metabolic disorders, and autoimmune diseases. Services are delivered under GLP and GCP compliance with MHRA and AAALAC accreditation.
Differentiator
Problem solved
Functional benefit
Products and services
- Bioanalysis
Quantifiable outcome
- 17,000+ studies completed
- +3 more outcomes
Companies that use Pharmidex
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles3 records
Pharmidex technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Pharmidex partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- Multi-programme Biotech PartnercoreIntegrated pharmacology, bioanalysis, and safety support through IND-enabling programmes. Represents collaborative drug development partnerships with biotech companies.
- Academic ConsortiumcoreStandardised in vivo execution and centralised bioanalysis across academic institutions for translational research collaborations.
Scale indicators12 records
Recent moves4 records
Expansion highlights4 records
Pharmidex competitors and assessment
Company assessmentBroad incumbents
- WuXi AppTec: Global CRO/CDMO providing preclinical toxicology, bioanalysis, DMPK and integrated drug discovery. Broad incumbent competing with Pharmidex across virtually all service lines from larger, integrated platform.
- Charles River Laboratories: Global preclinical and discovery CRO offering in vivo pharmacology, safety assessment, bioanalysis and DMPK across modalities. Most directly comparable incumbent in Pharmidex’s core preclinical CRO market, though vastly larger and broader in scope.
- Pharmaron: Global CRO providing integrated drug discovery, preclinical and bioanalytical services with strong UK presence. Closest large-scale peer to Pharmidex’s integrated preclinical + bioanalysis offering, competing on similar capabilities with broader geographic footprint.
- Eurofins Scientific: Global bioanalytical and laboratory testing services provider with significant preclinical and pharmacology operations. Broad incumbent competing with Pharmidex on bioanalysis, DMPK and central laboratory services.
Direct peers
- Sequani: UK-based preclinical CRO providing general toxicology, safety pharmacology and DMPK. Directly comparable UK competitor with overlapping GLP in vivo services and similar customer base.
- Crown Bioscience: Preclinical CRO specialising in oncology and metabolic disease models, translational research and bioanalysis. Direct peer to Pharmidex’s oncology and metabolic therapeutic area services.
- Inotiv: US-based preclinical CRO and research models provider offering toxicology, DMPK, bioanalysis and vivarium services. Highly comparable to Pharmidex on AAALAC-accredited in vivo toxicology and bioanalysis, primarily serving small-to-mid biopharma.
- Concept Life Sciences: UK-based CRO offering drug discovery, medicinal chemistry, DMPK and bioanalytical services. Comparable peer for Pharmidex’s preclinical and in silico discovery offerings, with overlapping customer segments in small-mid biopharma.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights7 records
Customer concentration
Pharmidex social profiles
Digital presencePharmidex compliance and trust
Trust signalCompliance4 records
Pharmidex financial estimates
Financial estimateRevenue estimate
Valuation estimate
Pharmidex leadership team
Management profileNumber of profiles
Profiles3 records
Pharmidex funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Pharmidex M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Pharmidex
What does Pharmidex do?
Pharmidex is a UK-based preclinical Contract Research Organisation (CRO) that delivers fee-for-service drug discovery and development support across three integrated pillars: Bioanalysis (biomarker analysis, discovery and regulatory bioanalysis, drug metabolism, physicochemical assessment, flow cytometry, haematology), Preclinical Services (histology, inflammation, in silico drug discovery, medicinal chemistry, medical device testing, pharmacokinetics, toxicology, vivarium), and Clinical Services (clinical chemistry, haematology, regulatory bioanalysis). The company serves pharma, biotech, and academic clients with GLP-, GCP-, MHRA-, and AAALAC-accredited workflows across therapeutic areas including CNS, oncology, stroke, respiratory, metabolic, and autoimmune diseases.
Is Pharmidex a public or private company?
Pharmidex is a private company. It is classified as unknown and is currently operating.
When was Pharmidex founded?
Pharmidex was founded in 2002. It employs 11 to 50 people.
Where is Pharmidex based?
Pharmidex is headquartered in London, United Kingdom, in the Europe region.
How does Pharmidex make money?
One revenue line is on record: preclinical Contract Research Services.
Who are Pharmidex's main competitors?
Broad incumbents on record are WuXi AppTec, Charles River Laboratories, Pharmaron and Eurofins Scientific. Direct peers are Sequani, Crown Bioscience, Inotiv and Concept Life Sciences.
Does Pharmidex have an API?
No public API is recorded for Pharmidex.
What industry is Pharmidex in?
Pharmidex's product category is Preclinical Contract Research Services. Its primary akta.pro industry code is HLAGAAAB, Preclinical CROs (Discovery/Pharmacology/DMPK), with a secondary code of HLAGAFAC, DMPK / ADME & Bioanalysis. Its NAICS code is 5417 and its SIC code is 8731.